Evidence map›Paper›PMID 29577613›Full record

ArticleThoracic cancer2018

Molecular biological analysis in a patient with multiple lung adenocarcinomas.

Tomoshige Wakayama, Hirokuni Hirata, Shunsuke Suka, Kozo Sato, Masamitsu Tatewaki, Ryosuke Souma, Hideyuki Satoh, Motohiko Tamura, Yuji Matsumura, Hiroki Imada and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Tomoshige WakayamaDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Hirokuni HirataDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0002-8953-4070
Shunsuke SukaDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Kozo SatoDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Masamitsu TatewakiDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Ryosuke SoumaDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Hideyuki SatohDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Motohiko TamuraDepartment of Thoracic and Cardiovascular Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Yuji MatsumuraDepartment of Thoracic and Cardiovascular Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Hiroki ImadaDepartment of Pathology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Kumiya SugiyamaDepartment of Pathology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Masafumi ArimaDepartment of Rheumatology, Dokkyo Medical University, Tochigi, Japan.
Kazuhiro KurasawaDepartment of Rheumatology, Dokkyo Medical University, Tochigi, Japan.
Takeshi FukudaTochigi Medical Center Shimotsuga, Tochigi, Japan.
Yasutsugu FukushimaDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Social Insurance Saitama Chuo Hospital · JPDokkyo Medical University · JPTochigi Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The utility of molecular biological analysis in lung adenocarcinoma has been demonstrated. Herein we report a rare case presenting as multiple lung adenocarcinomas with four different EGFR gene mutations detected in three lung tumors. After opacification was detected by routine chest X-ray, the patient, a 64-year-old woman, underwent chest computed tomography which revealed a right lung segment S4 ground-glass nodule (GGN). Follow-up computed tomography revealed a 42 mm GGN nodule with a 26 mm nodule (S6) and a 20 mm GGN (S10). Histopathology of resected specimens from the right middle and lower lobes revealed all three nodules were adenocarcinomas. Four EGFR mutations were detected; no three tumors had the same mutations. Molecular biological analysis is a promising tool for the diagnosis of primary tumors in patients with multiple lung carcinomas of the same histotype, enabling appropriate treatment.

Indexed as

Adenocarcinoma of LungErbB ReceptorsFemaleHumansLungMiddle AgedMutationNeoplasms, Multiple PrimaryEGFR protein, humanErbB ReceptorsAdenocarcinoma of the lungEGFR mutationsmolecular biological analysismultiple lung cancer

Identifiers

PMID29577613
PMCPMC5928370
OpenAlexW2791809760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.